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ABSTRACT
In this study, we aimed to show the synergistic apoptotic effects of imatinib/fludarabine
combination in human K562 chronic myleloid leukemia (CML) cells. There was a significant
increase in cytotoxicity of combination of imatinib and fludarabine as compared to any agent
alone. On the other hand, combination of both agents induced apoptosis significantly as con-
firmed by increases in caspase-3 enzyme activity and decreases in mitochondrial membrane
potential. As a summary, the results of this study strongly suggest that combination of imatinib
and fludarabine induced cell death synergistically comparing to only imatinib or fludarabine in
human K562 CML cells.
INTRODUCTION
Chronic myeloid leukemia is a hematopoietic stem cell dis-
order induced by Philadelphia chromosome that results from the
reciprocal translocation between chromosome 9 and 22. ABL
and BCR genes transferred from the chromosome 9 and 22, re-
spectively, generate the BCR/ABL hybrid oncogene. BCR/ABL
fusion protein has a constitutive tyrosine kinase activity due to
the presence of kinase domain of ABL. This fusion protein op-
erates several signaling pathways causing uncontrolled cellular
proliferation, reduction of apoptosis, and decrease in the cellular
adhesion (1–6).
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In recent years, imatinib (imatinib mesylate, STI571,
Gleevec) has become a widely used anticancer agent for the
treatment of CML patients. Imatinib is able to recognize 21
amino acid in the ATP-binding side of the BCR/ABL and thus
can prevent uncontrolled activities of BCR/ABL. It has been re-
sponded hematologically and cytogenetically well by the CML
patients in the beginning of the treatment but resistance to ima-
tinib observed in the blast crisis phase and in proceeding times
has become one of the major problems for the treatment of CML
patients (2, 7, 8). Resistance to imatinib can be divided into two
groups as primary and secondary resistance that emerges from
the beginning of the treatment and after the treatment, respec-
tively. There are several approaches that have been developed
to overcome imatinib resistance. Increment in the imatinib
dose, development and application of the other tyrosine kinase
inhibitors, or combination of imatinib with other anticancer
agents are preferred to overcome imatinib resistance (8).
Fludarabine is a nucleoside purine analogue that inhibits the
DNA synthesis and repair (9). Phosphorylated form of fludara-
bine as 2-F-ara-A is transported into the cell and it is rephospho-
rylated to 2-F-ara-ATP. This form of fludarabine has the ability
to prevent the activity of enzymes involved in DNA synthesis
and DNA repair. Inhibition of DNA polymerase alpha, DNA
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primase, ligase, and reductase induces DNA damage and arrest
the cell cycle (10–13).
In cancer therapy, it is possible to increase the effect of an
agent with another agent and also remission of the resistance
by combination therapy. Different agents influencing a vari-
ety of oncogenic pathways were used in combination to obtain
synergistic cytotoxic effect. For optimizing individual therapy,
combination therapy is a significant choice. An exciting research
on the mathematical framework to CML shows that a combina-
tion of targeted drugs with different specialties can overcome
the resistance. By this way, the principles that form the basis of
the resistance emergence in cancers treated with targeted drugs
with imatinib were shown by mathematical framework (14).
In this study, we tried to increase the sensitivity of human
K562 CML cells to imatinib by combination of imatinib with
fludarabine and to show the apoptotic mechanisms involved in
cell death.
METHODS
Cell lines and culture conditions
K562 human CML cells were obtained from the German
Collection of Microorganisms and Cell Cultures. These cells
were maintained in RPMI 1640 medium containing 10% fe-
tal bovine serum and 1% penicillin-streptomycin (Invitrogen,
USA) at 37◦C in 5% CO2.
Determination of cell proliferation by XTT
IC50 values (dose of the drugs in which 50% of the cells can
survive) of fludarabine and imatinib were determined by XTT as
described previously (15). Briefly, 2 × 104 cells were maintained
in 96-well plates with 200 µL growth medium in the absence or
presence of increased doses of fludarabine and imatinib. Then,
they were incubated at 37◦C in 5% CO2 for 72 hr. The cells
were treated with 40 µl of XTT reagent for more hours and then
the plates were read under 490 nm wavelength by Elisa reader
(Thermo Electron Corporation Multiskan Spectrum, Finland).
According to the cell survival plots, IC50 values of the drugs
were calculated.
Measurement of caspase-3 enzyme activity
The caspase-3 colorimetric assay kit (R&D Systems, USA)
was used to determine the caspase-3 enzyme activity of the cells.
At the beginning, cells that had been induced to apoptosis were
collected by centrifugation at 1,000 rpm for 10 min. Then, 100
µL of cold lysis buffer (1X) was added to the cells with the
aim of resuspending them. After the lysation, cells were kept
on ice for 10 min. Then, they were centrifuged at 14,000 rpm
for 1 min. Supernatants were taken into new microcentrifuge
tubes and 20 µL assay buffer (5X), 25 µL of sample, 50 µL of
sterilized water, and 5 µL of caspase-3 colorimetric substrate
were added into 96-well plates with the aim of preparing the
reaction mixture. The reaction mixture was incubated at 37◦C
in 5% CO2 for 2 hr. Finally, the plate was read under 405
nm wavelength light (Thermo Electron Corporation Multiskan
Spectrum, Finland).
Measurement of the loss of mitochondrial
membrane potential
Mitochondrial membrane potential (MMP) of K562 human
CML cells was determined using APO LOGIX JC-1 Assay Kit
(Cell Technology, USA). First, the cells that had been induced
apoptosis were collected by centrifugation at 1,000 rpm for 10
min. Then, supernatants were removed and 500 µL of JC-1 dye
was added onto the pellets and they were incubated at 37◦C
in 5% CO2 for 15 min. After the incubation time, they were
centrifuged at 1,000 rpm for 5 min. Then, supernatants were re-
moved and the dyed cells were resuspended again with 2 mL of
assay buffer. They were centrifuged for 5 min at 1,000 rpm. 500
µL assay buffer was added onto the pellets and 150 µL from
each of them was added into the 96-well plate. The aggregate
red form has absorption/emission maxima of 585/590 nm and
the green monomeric form has absorption/emission maxima of
510/527 nm. The plate was read in these wavelengths by fluo-
rescence Elisa reader (Thermo Varioskan Spectrum, Finland).
Detection of apoptotic cells by by anexinV by
flow cytometry
Apoptotic cell death was evaluated by using Annex-
inV/FITC and propidium iodide double staining method based
on apoptosis-related cell membrane modifications. First, cells
that had been induced to apoptosis were washed with cold
phosphate-buffered saline and then resuspended in 1X bind-
ing buffer. One hundred µl from each solution was transferred
to microcentrifuge tubes. Five µl Annexin V-FITC and 5 µL
propidium iodide (PI) were added on the cells. After gentle vor-
texing, they were incubated for 15 min at room temperature in
the dark. Four hundred µl of 1X binding buffer was then added
into each tube and they were analyzed by flow cytometry (BD
Facscanto flowcytometry, Belgium) within 1 hr.
RESULTS
Cytotoxic effect of imatinib and fludarabine is
dose dependent on K562 human CML cells
IC50 values of imatinib and fludarabine were determined
by XTT cell proliferation assay. K562 cells were exposed to
stepwise increasing doses of drugs for 72 hr and proliferations of
the cells were measured. XTT results showed that proliferation
of the cells were 12, 16, and 26% decreased in response to 1, 10,
and 100 nM imatinib, respectively (Figure 1). There were 28,
66, 74, 80 and 83% decreases in the proliferation in 1, 5, 10, 100,
and 500 nM fludarabine applied K562 cells, respectively (Figure
2). IC50 values of imatinib and fludarabine were calculated as
280 and 3.3 nM, respectively.
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Figure 1. Effects of imatinib on the growth of K562 cells. The
IC50 concentration of imatinib was calculated from cell proliferation
plots. The XTT assays were performed using triplicate samples in
at least two independent experiments. Statistical significance was
determined using two-way analysis of variance, and p < .05 was
considered significant.
Synergistic effect of imatinib and fludarabine
combination on K562 human CML cells
proliferation
Proliferation of the cells which were exposed to only 0.1, 1,
10, 100, and 500 nM imatinib was decreased 6, 12, 16, 26, 80,
and 84%, respectively, while the application of the same doses
of imatinib in combination of 3.3 nM fludarabine decreased the
proliferation of K562 cells 80, 83, 83, 85, and 88%, respectively
(Figure 3). These results show that the combination of imatinib
and fludarabine has much more cytotoxic effect than any agent
alone on K562 human CML cells.
Figure 2. Effects of fludarabine on the growth of K562 cells. The
IC50 concentration of fludarabine was determined by XTT assay
for each cell line as described. The XTT assays were performed
using triplicate samples in at least two independent experiments.
Statistical significance was determined using two-way analysis of
variance, and p < .05 was considered significant.
Figure 3. Effects of fludarabine and imatinib combination on the
growth of K562 cells. Cytotoxicity was determined by the XTT cell
proliferation test in a 72 hr culture. The XTT assays were performed
using triplicate samples in at least two independent experiments.
Statistical significance was determined using two-way analysis of
variance, and p < .05 was considered significant.
Synergistic effects of combination of imatinib
and fludarabine on the caspase-3 enzyme
activity
As shown in Figure 4, exposures of 3.3 nM fludarabine, 0.1
and 1 nM imatinib alone, increased caspase-3 enzyme activity
1.36-, 1.16- and 1.26-fold in K562 cells as compared to untreated
controls, respectively. On the other hand, there were 1.73- and
1.8-fold increases in caspase-3 enzyme activity in combination
of the same doses of imatinib with 3.3 nM fludarabine comparing
to untreated controls, respectively. (Figure 4).
Figure 4. Percentage changes in caspase-3 enzyme activity in
fludarabine and imatinib combination or any agent alone exposed
K562 Cells. The results are the means of two independent experi-
ments. p < .05 was considered significant.
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Figure 5. Percentage changes in Cytoplasmic/Monomeric JC-1 in
fludarabine and imatinib combination or any agent alone exposed
K562 Cells. The results are the means of two independent experi-
ments. p < .05 was considered significant.
Loss of the mitochondrial memrane potential
in response to the combination of imatinib and
fludarabine in K562 cells
Treatment with imatinib/fludarabine combination caused a
significant loss of MMP, as measured by increased accumula-
tion of cytoplasmic/monomeric form of JC-1, in K562 cells as
compared with any agent alone. There were 1.16- and 1.30-
fold increases in cytoplasmic/monomeric JC-1 in 0.1 and 1
nM imatinib-applied K562 cells, respectively, while 3.3 nM
fludarabine increased cytoplasmic/mitochondrial 1.22 fold by
itself (Figure 5). On the other hand, the same concentra-
tions of imatinib with 3.3 nM fludarabine increased cytoplas-
mic/mitochondrial JC-1 1.65- and 1.92-fold as compared to
untreated control group, respectively. (Figure 5).
Imatinib and fludarabine combination induced
cell death in CML cells more than any
agent alone
Apoptosis and cell viability in K562 cells were measured
by AnnexinV-FITC staining by flow cytometry. There were 30,
22, and 23% increases in cell death in response to 3.3 nM
fludarabine, 0.1 and 1 nM imatinib in K562 cells, respectively.
Exposure of K562 cells to the combination of 3.3 nM fludarabine
and 0.1 or 1 nM imatinib increased the percentage of cell death
to 36, and 42%, respectively, as compared to untreated controls
[Figures 6(A) and 6(B)].
DISCUSSION
Inhibition of BCR/ABL constitutive tyrosine kinase activity
is an important breakthrough in the treatment of CML patients.
While imatinib is a well-tolerated agent, it shows very high
rates of hematological and cytogenetical responses. However,
the emergence of resistance to imatinib has been recognized as a
major problem for the treatment of CML patients. Combination
of the imatinib with other nonoverlapping mechanism of action
combination therapies is a good alternative strategy to manage
the resistance problem (16).
Fludarabine, a purine nucleoside analogue, inhibits repli-
cation of DNA through interacting not only with DNA poly-
merase but also with ribonucleotide reductase (17). Fludarabine
has shown significant cytotoxicity as it is combined with cy-
clophosphamide, mitoxantrone, dexamethasone, and rituximab
for the treatment of non-Hodgkins lymphomas. On the other
hand, fludarabine has also been used for the treatment of acute
myeloid leukemia in combination with cytarabine and granu-
locyte colony-stimulating factor (18, 19). In the same way, our
results have shown that both imatinib and fludarabine inhibited
proliferation of K562 CML cells in a dose-dependent manner.
Both of the agents have very high cytotoxic effects even in
nanomolar concentrations. IC50 value of imatinib and fludara-
bine were calculated to be 280 nM and 3.3 nM in K562 cells,
respectively. There are some recent researches, which indicate
accelerated synergistic apoptotic effects of imatinib and/or flu-
darabine with a combination of other anticancer agents in hema-
tological malignancies. Effectiveness of imatinib was increased
synergistically with lonafarmib for the treatment of patients with
CML. The importance of this study comes from the failure of
patients, when the imatinib was used as a single agent. Usage
of lonafarmib for patients who shows resistant to imatinib is
well tolerated by the patients (20). Combination of imatinib
with mitoxantrone/etoposide or cytarabine also have been used
by Fruehauf and his colleagues and their results revealed that
combination of these agents make CML patients more sensitive
to imatinib (21). On the other hand, combination of fludara-
bine with mylotarg, cytarabine (Ara-C), or cyclosporine has
significant cytotoxicity on acute myelogenous leukemia and
acute lymphoblastic leukemia patients (22). Adaphostin, ox-
aliplatin, or cyclophosphamide in combination with fludarabine
was also shown to induce apoptosis significantly in chronic
lymphocytic leukemia (CLL) cells (23, 24). In this study, we
combined 3.3 nM fludarabine with increasing concentrations
of imatinib and observed synergistic antiproliferative effects on
K562 cells. While imatinib could not show cytotoxic effects
on K562 cells in 0.1, 1, 10, and 100 nM concentrations, com-
bination of these doses of imatinib, with 3.3 nM fludarabine
resulted in more that 80% reduction in proliferation of K562
cells. In parallel with our experimental results, Korycka and col-
leagues have shown that there were synergistic cytotoxic effects
of imatinib in combination with cladribine (2-CdA), a purine
analogue, on the normal and chronic myelogenous leukemia
progenitor cells. It was clearly shown by this study that imatinib
together with 2-CdA at different concentration combinations
significantly blocked the colony growth of CML granulocyte-
macrophage progenitor cells (CFU-GM), as compared either to
the control or to any agent used alone (25). We conducted three
more molecular approaches in order to confirm the synergis-
tic effects of imatinib and fludarabine in addition to XTT cell
proliferation data. The results of changes in caspase-3 enzyme
activity, loss of mitochondrial membrane potential, and changes
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Figure 6. Percentage changes in cell death by anexinV-FITC in imatinib and fludarabine combination or any agent alone exposed K562 cells.
The results are the means of two independent experiments. The error bars represent the standard deviations, and when not seen, they are
smaller than the thickness of the lines on the graphs. p < .05 was considered significant.
in cell death and viability assays showed in agreement that com-
binations of very low subtoxic concentrations of imatinib (0.1
and 1 nM) in combination with 3.3 nM fludarabine resulted in
synergistic apoptotic effects on K562 cells as compared to any
agent alone. The results of caspase-3 enzyme activity and mi-
tochondrial membrane potential experiments also revealed that
combination of these agents induce apoptosis through MMP and
caspase-3-dependent pathway.
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In this study, we examined possible synergistic apoptotic ef-
fects of imatinib and fludarabine and the mechanisms responsi-
ble for induction of apoptosis in human K562 CML cells. While
fludarabine inhibits replication of DNA, imatinib inhibits all
the signaling pathways regulated by oncogenic BCR/ABL. Our
data suggested that fludarabine elevated the chemosensitivity of
BCR/ABL positive K562 cells to imatinib. This is most proba-
bly because inhibition of replication of DNA besides inhibiton
of strong oncogene, BCR/ABL, created strong synergism. This
in vitro data by being supported with clinical data may open the
way of more effective treatment of CML.
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